Corient Private Wealth
KNSA icon

Corient Private Wealth’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Corient Private Wealth’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$515K Sell
8,050
-6
-0.1% -$311 ﹤0.01% 2207
2026
Q1 		$388K Buy
+8,056
New +$357K ﹤0.01% 2172

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Corient Private Wealth's KNSA Position: Q2 2026 in Review

Corient Private Wealth reduced its Kiniksa Pharmaceuticals (KNSA) stake by 0.07% in Q2 2026, selling an estimated $311 and leaving 8,050 shares worth $515K. The position accounts for ﹤0.01% of the portfolio, ranked #2207.

Corient Private Wealth first reported a position in KNSA in Q1 2026 and has held it in 2 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Corient Private Wealth held 8,050 shares of Kiniksa Pharmaceuticals worth $515K as of Q2 2026.
  • Corient Private Wealth sold 6 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $311.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2207 holding.
  • Corient Private Wealth first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.